C
37.45
-1.22 (-3.15%)
| Previous Close | 38.67 |
| Open | 38.50 |
| Volume | 1,212,209 |
| Avg. Volume (3M) | 1,127,285 |
| Market Cap | 3,913,225,472 |
| Price / Earnings (TTM) | 33.14 |
| Price / Sales | 8.80 |
| Price / Book | 7.92 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2024 - 4 Nov 2024 |
| Profit Margin | 22.12% |
| Operating Margin (TTM) | 22.03% |
| Diluted EPS (TTM) | 1.13 |
| Quarterly Revenue Growth (YOY) | 39.10% |
| Quarterly Earnings Growth (YOY) | 28.90% |
| Total Debt/Equity (MRQ) | 0.95% |
| Current Ratio (MRQ) | 5.57 |
| Return on Assets (TTM) | 12.91% |
| Return on Equity (TTM) | 24.75% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Corcept Therapeutics Incorporat | Bullish | Bullish |
Stockmoo Score
1.4
| Analyst Consensus | 5.0 |
| Insider Activity | -1.5 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 1.40 |
|
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 11.55% |
| % Held by Institutions | 87.54% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 78.00 (Canaccord Genuity, 108.28%) | Buy |
| Median | 71.50 (90.92%) | |
| Low | 45.00 (HC Wainwright & Co., 20.16%) | Buy |
| Average | 66.50 (77.57%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 40.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Truist Securities | 30 Sep 2024 | 76.00 (102.94%) | Buy | 46.28 |
| Piper Sandler | 18 Sep 2024 | 67.00 (78.91%) | Buy | 42.27 |
| 30 Jul 2024 | 38.00 (1.47%) | Buy | 36.12 | |
| Canaccord Genuity | 31 Jul 2024 | 78.00 (108.28%) | Buy | 38.67 |
| 30 Jul 2024 | 38.00 (1.47%) | Buy | 36.12 | |
| HC Wainwright & Co. | 30 Jul 2024 | 45.00 (20.16%) | Buy | 36.12 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 29 Jul 2024 | Announcement | Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update |
| 22 Jul 2024 | Announcement | Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |